Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction

Tetsuro Tsujimoto1, Hiroshi Kajio1

  • 1Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo, Japan.

Insights

Low diastolic blood pressure (DBP) significantly increases cardiovascular risks in heart failure with preserved ejection fraction (HFpEF) patients. This finding highlights the importance of monitoring DBP for adverse outcomes in this population.

Area of Science:

  • Cardiology
  • Clinical Research
  • Hypertension Management

Background:

  • The prognostic implications of low diastolic blood pressure (DBP) in patients with heart failure with preserved ejection fraction (HFpEF) remain unclear.
  • Existing research has not definitively established whether reduced DBP poses a risk for cardiovascular events or mortality in this specific patient group.

Purpose of the Study:

  • To investigate the association between low diastolic blood pressure (DBP) and the risk of cardiovascular events and death in patients diagnosed with heart failure with preserved ejection fraction (HFpEF).

Main Methods:

  • Utilized data from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.
  • Analyzed a composite primary outcome including all-cause death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure.
  • Employed multivariable Cox proportional hazard models to assess hazard ratios (HRs) for different DBP categories (<60, 60-69, 70-79, and ≥90 mmHg) compared to a reference range (80-89 mmHg).

Main Results:

  • The study included 3417 HFpEF patients with controlled blood pressure; 881 experienced primary outcome events during a 3.0-year follow-up.
  • Significantly higher adjusted HRs for primary outcome events were observed in patients with DBP <60 mmHg (HR: 2.19) and 60-69 mmHg (HR: 1.52) compared to the 80-89 mmHg reference group.
  • Low DBP (<70 mmHg) was associated with increased risks of all-cause death, major cardiovascular events, and heart failure hospitalizations, but not stroke. This association was evident in HFpEF patients with systolic blood pressure ≥120 mmHg.

Conclusions:

  • A low diastolic blood pressure (DBP) is a significant risk factor for adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF).
  • The findings underscore the clinical importance of considering DBP thresholds in risk stratification and management strategies for HFpEF patients.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360